Natixis’s Privia Health PRVA Stock Holding History

Natixis’s Portfolio PRVA Stock Details PRVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,000	Closed	-$443K	–	1299
2022 Q3	$443K	Buy	+13,000	New	+$481K	﹤0.01%	904

Other funds holding PRVA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Natixis's PRVA Position: Q4 2022 in Review

Natixis sold out of Privia Health (PRVA) in Q4 2022, closing a stake of 13,000 shares — an estimated $443K sold.

Natixis first reported a position in PRVA in Q3 2022 and held it in 1 quarter. The position peaked at $443K in Q3 2022. 192 funds tracked by Wall St. Rank hold PRVA as of Q4 2022.

Natixis reported no remaining Privia Health position as of Q4 2022 after selling out during the quarter.
Natixis sold 13,000 Privia Health shares in Q4 2022, an estimated $443K.
Natixis first reported a position in Privia Health in Q3 2022 and held it in 1 quarter.
Natixis's Privia Health position peaked at $443K in Q3 2022.
192 funds tracked by Wall St. Rank held Privia Health as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.